Key result
Cardioneuroablation is a promising experimental method for treating refractory neurocardiogenic syncope, with reported effectiveness in preventing recurrence of vasovagal syncope ranging from 80-100%.
Why the study?
Does cardioneuroablation prevent syncope in patients with neurocardiogenic syncope?
Does cardioneuroablation prevent syncope in patients with neurocardiogenic syncope?
Cardioneuroablation is a promising experimental treatment for refractory neurocardiogenic syncope, targeting the intrinsic cardiac autonomic nervous system to prevent excessive vagal activation.
Should not yet alter practice for refractory neurocardiogenic syncope; leaves open the need for randomized trials to establish efficacy.
We are presenting the ablation of parasympathetic ganglia in the atria as a new method of treatment of vasovagal and other neurocardiogenic syncope. This method, shifting the balance of the autonomic nervous system in the sympathetic direction, is directed to the immediate cause of syncope which is excessive activation of the vagus nerve. Its effectiveness in the annual observation is within 80-100%. This method offers a great chance to improve the quality of life in patients with reflex syncope what have not been prevented by conventional treatment.
No takes yet. Share an insight, caveat, or question.
Koźluk et al. (2022) conducted a review in Neurocardiogenic syncope. Cardioneuroablation was evaluated. Cardioneuroablation is a promising experimental method for treating refractory neurocardiogenic syncope, with reported effectiveness in preventing recurrence of vasovagal syncope ranging from 80-100%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: